Q4 2025 Delcath Systems Inc Earnings Call Transcript
Key Points
- Delcath Systems Inc (DCTH) achieved over 40% volume growth and record annual revenue of $85.2 million in 2025.
- The company operates 28 active treatment centers and plans to expand to 40 by the end of 2026.
- Positive feedback from oncologists highlights the effectiveness of PHP in treating liver metastases from uveal melanoma.
- The Chopin trial data shows significant improvements in survival rates when PHP is combined with checkpoint inhibitors.
- Delcath Systems Inc (DCTH) ended the year with approximately $91 million in cash and investments, indicating strong financial health.
- Research and development expenses increased significantly, from $13.9 million in 2024 to $29.2 million in 2025.
- Selling, general, and administrative expenses rose to $43 million in 2025, up from $29.6 million in 2024.
- The company anticipates a seasonal decline in capacity during the late summer, which could impact revenue.
- There is variability in the number of new patient starts per site, which can affect revenue projections.
- The company expects R&D expenses to increase by nearly 90% in 2026, which could impact profitability.
Greetings and welcome to Dellcath Systems 4th quarter 2025 earnings conference call. (Operator Instructions)
Please note this conference is being recorded. It is now my pleasure to turn the conference over to Mr. David Hoffman, Delca's general counsel.
Thank you. You may begin.
Thank you and welcome to Delcat Systems 4th quarter and year-end 2025 earnings call. With me on the call are Gerard Michel, Chief Executive Officer, Sandra Pinnell, Chief Financial Officer, Kevin Muir, General Manager, Interventional oncology, Boyo Vukovic, Chief Medical Officer, and Martha Rook, Chief Operating Officer.
This statement is made pursuant to the safe harbor for forward-looking statements described in the Private Securities Litigation Reform Act of 1,995. All statements made on this call, with the exception of historical facts, may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1,933 and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
